Individual QCMD 2017 Human Cytomegalovirus Report DNA EQA ...

Intended Results / Panel Composition

Sample Code SampleConte nt

Matrix SampleRe lat ionships

De te ct ionFre que ncy

SampleStatus

Conse nsus(Copie s/ml)

Range

(Log ) (n)

CMVDNA17S-01 CMV(AD169)

Plasma D2, DS1_2 Detected EDUCATIONAL 2.426 34 1.826 -3.816

CMVDNA17S-02 CMV(Clinical)

Plasma D3, DS2_1 FrequentlyDetected

CORE 3.438 42 1.934 -3.924



CORE 3.901 41 3.264 -5.975









CORE 3.870 42 3.279 -5.535



CORE 3.431 41 1.230 -4.271

CMVDNA17S-09 CMVNegative

Plasma Negative CORE N/A N/A N/A



CORE 3.876 42 2.551 -5.775

[1]

[2] [3]

[4]

[5]

10

IndividualReport

QCMD 2017 Human CytomegalovirusDNA EQA Programme

Catalogue Code :QAV014120

Re f Code :CMVDNA17

Challe nge :S

Analysis Type :Qualitative and Quantitative

Dat ase t : Re p o rt UID: Lab o rat o ry

Q C M D , Te ch n o l o g y Te rrace , To d d C amp u s , We s t o fSco t l an d Sc i e n ce Park , Gl asg o w, G20 0 XA Te l : +44 (0 ) 1419 45 6 474, Fax: +44 (0 ) 141 9 45 579 5 We b : www.q cmd .o rg

Pag e 1 o f 34 Issu e D ate : 0 1 N o v 20 17 R e p o rt au th o ri se d b y th e Q C M D Exe cu t i ve (1) A U KAS acc re d i te d p ro f i c i e n cy te s t i n g p ro vi d e r N o .438 5

[1] Sample Re lat ionships: Ind icate s the re latio nship s o f the samp le s within this challe ng e . Dilutio n se rie s are ind icte d b y 'DS1' withe ach p ane l me mb e r in the d ilutio n se rie s re p re se nte d b y a numb e r in o rd e r o f titre , whe re DS1_1 re p re se nts the hig he st titre withinthat d ilutio n se rie s. Furthe r d ilutio n se rie s are ind icate d b y 'DS2' 'DS3' e tc. If o ne d up licate p air is p re se nt this is ind icate d b y 'D1' .Furthe r d up licate p airs are ind icate d b y 'D2' , 'D3' e tc.[2] De t e ct ion Fre que ncy: To aid q ualitative analys is e ach p ane l me mb e r is assig ne d a fre q ue ncy o f d e te ctio n. This is b ase d o nthe p e e r g ro up co nse nsus o f all q ualitative re sults re turne d fro m p artic ip ants within the EQA challe ng e / d is trib utio n. [3] Sample St at us: EQA samp le s are d e fine d as " CORE" o r " EDUCATIONAL" . Co re p ro fic ie ncy samp le s are re vie we d b y theQCMD Scie ntific Exp e rt(s). This is o n the b asis o f sc ie ntific info rmatio n, c linical re le vance , curre nt l i te rature and , whe re ap p ro p riate ,p ro fe ssio nal c linical g uid e line s. Partic ip ating lab o rato rie s are e xp e cte d to re p o rt co re p ro fic ie ncy samp le s co rre ctly within theEQA challe ng e / d is trib utio n.[4] Conse nsus (Copie s/ml): Me an co nse nsus (Lo g ) calculate d fro m d ata re turne d b y p artic ip ants with o utl ie rs re mo ve d andnumb e r o f q uantitative re sults (n) re turne d fo r e ach p ane l me mb e r. [5] Range : Maximum and minimum q uantitative value (Co p ie s/ml) re p o rte d b y p artic ip ants within this challe ng e witho ut o utl ie rsre mo ve d . For further details please refer to the current participant manual.

Your Summary Results

Units Copies/ml

EQA Asse ssme nt Group Real- time In-House PCR

Core Pane l De te ct ion (Qualitat ive ) Score 0

Core Pane l Est imat ion (Quant itat ive ) Score 3

10

[1]

[2]

[3]

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





Sample Code Unitage EQAAsse ssme ntGroupConse nsus

SD Quant itat ive Re sult Qualitat ive Re sult

YourRe sult

Est imat ionScore

Pe rce ntageCorre ct(All)

YourRe sult

De te ct ionScore

CMVDNA17S-01 Copies/ml 2.386 0.234 2.449 0 92.3 Positive 0




CMVDNA17S-05 Copies/ml 2.304 0.418 LOD/NR - 92.3 Positive 0

CMVDNA17S-06 Copies/ml 2.554 0.294 LOD/NR - 94.9 Positive 0



CMVDNA17S-09 Copies/ml N/A - LOD/NR N/A 98.7 Negative 0


All q uantitative value s ab o ve e xp re sse d in Lo g Co p ie s/ml.[1] EQA Asse ssme nt Group: To aid d ata analys is, p artic ip ant re sults are g ro up e d acco rd ing to the mo le cularamp lificatio n/d e te ctio n me tho d sp e cifie d within the ir mo le cular wo rkflo w fo r this challe ng e / d is trib utio n. Fo r furthe r d e tails re fe r tothe Additional Information: Individual Panel Member Analysis se ctio n o f this re p o rt.[2] Core Pane l De t e ct ion (Qualit at ive ) Score : An o ve rall co re p ane l d e te ctio n sco re p ro vid e d p e r challe ng e / d is trib utio n.[3] Core Pane l Est imat ion (Quant it at ive ) Score : An o ve rall co re p ane l e stimatio n sco re p ro vid e d p e r challe ng e / d is trib utio n.[4] EQA Asse ssme nt Group Conse nsus: The me an value fo r all re sults within yo ur EQA asse ssme nt g ro up .[5] SD: The stand ard d e viatio n fo r re sults fro m yo ur EQA asse ssme nt g ro up .[6 ] Your Quant it at ive Re sult : The q uantitative re sult yo u re turne d fo r e ach samp le within this EQA challe ng e . LOD/NR (l imit o fd e te ctio n o r no t re p o rte d ).[7] Est imat ion Score : Yo ur e stimatio n (q uantitative ) sco re s are calculate d b ase d o n yo ur variatio n fro m the co nse nsus fo r yo ur EQAasse ssme nt g ro up . With 0 (ze ro ) sco re d if the q uantitative value yo u re p o rte d is within o ne stand ard d e viatio n (SD) fro m yo ur EQAasse ssme nt g ro up co nse nsus, 1 (o ne ) if yo ur q uantitative value is b e twe e n o ne and two SDs, 2 (two ) if yo ur q uantitative value iswithin two and thre e SDs and 3 (thre e ) if yo ur q uantitative value is mo re than thre e SDs fro m the me an o f yo ur EQA asse ssme ntg ro up .[8 ] Pe rce nt age Corre ct (All): Pe rce ntag e o f d atase ts re p o rting the co rre ct q ualitative re sults fo r e ach p ane l me mb e rs.[9 ] Your Qualit at ive Re sult : The q ualitative re sult yo u re p o rte d fo r e ach samp le within this EQA challe ng e / d is trib utio n.[10 ] De t e ct ion Score : Yo ur d e te ctio n (q ualitative ) sco re s are b ase d o n the assig ne d d e te ctio n fre q ue ncy o f e ach p ane l me mb e rs,whe re 0 (ze ro ) is " hig hly satis facto ry" and 3 (thre e ) is " hig hly unsatis facto ry" . Sco re s are p ro vid e d fo r ind ivid ual p ane l me mb e rs. For further details please refer to the current participant manual.

[4]

[5]

[6 ]

[7]

[8] [9 ]

[10 ]

10

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





Core Panel Member Score Breakdown

Core Pane l Me mbe r Score Bre akdown - De t e ct ion: This fig ure g ive s yo u a b re akd o wn o f the q ualitative d e te ctio n sco re s fo r allq ualitative d atase ts re turne d within this EQA challe ng e / d is trib utio n ind e p e nd e nt o f the EQA asse ssme nt g ro up . Pane l d e te ctio nsco re s are g e ne rate d fro m o nly tho se p ane l me mb e rs that are d e fine d as “CORE”. Core Pane l Me mbe r Score Bre akdown - Est imat ion: This fig ure g ive s yo u a b re akd o wn o f the q uantitative e stimatio n sco re s fo r allq uantitative d atase ts re turne d within this EQA challe ng e / d is trib utio n ind e p e nd e nt o f the EQA asse ssme nt g ro up . Pane l e stimatio nsco re s are b ase d o n p o sitive co re p ane l me mb e rs o nly. Tho se d atase ts that d id no t re turn q uantitative value s fo r all co re samp le sare re p re se nte d b y ' -' . For further details please refer to the current participant manual.

Core Panel Members Score

Num

ber o

f Dat

aset

s

Cum

ulative PercentageDetection (Qualitative)

Numbe r of Dat ase t s Cumulat ive Pe rce nt age My Score

0 1 2 30

40

80

0

50

100

Core Panel Members Score

Num

ber o

f Dat

aset

s

Cum

ulative Percentage

Estimation (Quantitative)

Numbe r of Dat ase t s Cumulat ive Pe rce nt age My Score

0 1 2 3 4 5 6 7 8 -0

20

40

0

50

100

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





Duplicate Sample Performance Over Time

Series S1

Observation Details1: CMVDNA15C1-0 3 - CMVDNA15C1-0 2: Yo ur Variatio n -0 .0 33 (Co p ie s/ml): Ove rall Me an Variatio n 0 .0 0 1: Ove rall SD 0 .136 .2: CMVDNA15C2-0 5 - CMVDNA15C1-0 3: Yo ur Variatio n -0 .46 7 (Co p ie s/ml): Ove rall Me an Variatio n -0 .0 8 3: Ove rall SD 0 .30 3.3: CMVDNA16 C1-0 1 - CMVDNA15C2-0 5: Yo ur Variatio n -0 .0 56 (Co p ie s/ml): Ove rall Me an Variatio n -0 .0 49 : Ove rall SD 0 .28 6 .4: CMVDNA16 C1-0 3 - CMVDNA16 C1-0 1: Yo ur Variatio n -0 .0 72 (Co p ie s/ml): Ove rall Me an Variatio n -0 .0 0 3: Ove rall SD 0 .148 .5: CMVDNA16 C2-0 1 - CMVDNA16 C1-0 3: Yo ur Variatio n 0 .18 4 (Co p ie s/ml): Ove rall Me an Variatio n 0 .0 29 : Ove rall SD 0 .324.6: CMVDNA17S-0 3 - CMVDNA16 C2-0 1: Yo ur Variatio n -0 .0 77 (Co p ie s/ml): Ove rall Me an Variatio n 0 .0 41: Ove rall SD 0 .316 .7: CMVDNA17S-0 7 - CMVDNA17S-0 3: Yo ur Variatio n -0 .0 23 (Co p ie s/ml): Ove rall Me an Variatio n -0 .0 0 9 : Ove rall SD 0 .16 4.8: CMVDNA17S-10 - CMVDNA17S-0 7: Yo ur Variatio n 0 .112 (Co p ie s/ml): Ove rall Me an Variatio n 0 .0 30 : Ove rall SD 0 .156 .

QCMD mo nito rs yo ur lab o rato ry's p e rfo rmance o ve r time b ase d o n the re p o rte d q uantitative variatio n b e twe e n d up licate p ane lme mb e rs within the EQA challe ng e and , whe re ap p ro p riate , acro ss EQA challe ng e s.The me an variatio n and stand ard d e viatio n are calculate d fro m the q uantitative variatio n re p o rte d b y e ach p artic ip ant b e twe e nd up licate p ane l me mb e rs in the same unit o f me asure me nt o nce o utl ie rs have b e e n re mo ve d . (Se e 'Ob se rvatio n De tails ' )Pre vio us and curre nt o b se rvatio ns are p lo tte d o n the chart as the numb e r o f s tand ard d e viatio ns yo ur variatio n was fro m the me anvariatio n fo r all p artic ip ants who sub mitte d co rre sp o nd ing re sults in the same unitag e .Any re p o rte d variatio n g re ate r than ±3 SD wil l no t b e sho wn o n the g rap h, b ut yo ur variatio n value wil l b e p ro vid e d in re d in theObservation Details. Whe n " N/A" is d isp laye d fo r an o b se rvatio n, e ithe r no valid q uantitative re sults we re p ro vid e d o r the re was achang e in re p o rte d unitag e .

Observations

Stan

dard

Dev

iatio

ns F

rom

Mea

n

1 2 3 4 5 6 7 8-3

-2

-1

0

1

2

3

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





My Workflow DetailsThe details o f the workflow used to submit your results fo r this challenge.

Name CMV PCR

Descript io n

T arget s V cytomegalovirus

Assays Extraction - Roche - MagNA Pure 96 System Commercial

Kit Manufacturer: RocheKit Type: RNA and Viral NA Small Volume Kit

Amplification - Roche - LightCycler 480 System In-House

Type: RealtimeNAT Product Detection: Continuous DetectionNAT Product Detection Approach: TaqMan

Further Programme Details

Number of Participants 87

Number of Countries 28

Number of Respondents 82

Number of Datasets Submitted 93

Quantitative Results Returned (All) 72 (77.4%)

- Quantitative Results Returned (Copies/ml) 42 (58.3%)

- Quantitative Results Returned (IU/ml) 30 (41.7%)

Qualitative Results Returned 78 (83.9%)

EQA Programme AimsTo assess the pro ficiency o f laboratories in the detection and quantitation o f human cytomegalovirus (CMV).

Feedback and EnquiriesParticipants are encouraged to read the QCMD Participants' Manual, which can be downloaded from the QCMD website.

Any queries about this report should be addressed to the QCMD Neutral Office (neutralo [email protected]).

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





Additional Information: Individual Panel Member Analysis (Quantitative)Quantitative analysis fo r each panel member is provided in relation to your EQA assessment group. EQA assessmentgroups are established using the molecular workflow information reported by all participants within this EQA challenge /distribution. The principal level o f assessment is at the individual method level which is defined based on your reported“amplification/detection method” and o ther laboratories using the same or similar amplification/detection methods.

To allow meaningful assessment at the individual method level the EQA assessment group must consist o f 5 or moredatasets. If there are not sufficient datasets at the individual method level then your results will be included within a higherEQA assessment group based on whether it is a commercial o r in house techno logy/method. The highest levelassessment grouping is all reported results using the same unit o f measurement (i.e. Copies/ml or IU/ml).

The results below provide a breakdown of participant reported values on each o f the panel members within this EQAchallenge / distribution. Your result fo r each panel member is indicated by "your value". You can compare your value to the“mean” within your EQA assessment group and the overall consensus for each sample within this EQA challenge /distribution.

Key

CMVDNA17S-01 - Quant it at ive Result s Breakdo wn (Co pies/ml)




SampleStatus


Range

(Log ) (n)



10

Num

ber of Values in Groups

log Copies/ml

34

25

7

8

9

9

1.5 2 2.5 3 3.5 4

◉ Copie s/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House

● Re al- t ime In-House PCR

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





Groups be low n=5: Ab b o tt (n=1), Ab b o tt - Ab b o tt Re altime (n=1), ELITe ch Gro up (n=3), ELITe ch Gro up - Elite ch Elite Re al time kit(n=3), Anato lia Ge ne wo rks (n=1), Anato lia Ge ne wo rks - Anato lia Ge ne wo rks Bo sp ho re (n=1), Ro che (n=2), Ro che - Ro che Co b asTaq man (n=2), Diag e no d e (n=1), Diag e no d e - Diag e no d e Re al Time kit (n=1), Ge ne Pro o f (n=2), Ge ne Pro o f - Ge ne Pro o f Re al TimePCR kit (n=2)

Groups Rolle d Up: b io Me rie ux - b io Me rie ux R-g e ne Quant Kit (n=7), Q IAGEN - Q iag e n Artus Re al Time (n=8 )





SampleStatus


Range

(Log ) (n)



CORE 3.438 42 1.934 -3.924


Groups Rolle d Up: b io Me rie ux - b io Me rie ux R-g e ne Quant Kit (n=8 ), Q IAGEN - Q iag e n Artus Re al Time (n=9 )

10

Num


log Copies/ml

42

29

8

9

13

13

2 2.5 3 3.5 41.5 4.5

◉ Copie s/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


Range

(Log ) (n)



CORE 3.901 41 3.264 -5.975



10

Num


log Copies/ml

41

29

8

9

12

12

3 3.5 4 4.5 5 5.5 6 6.5

◉ Copie s/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


Range

(Log ) (n)



Groups be low n=5: Ab b o tt (n=1), Ab b o tt - Ab b o tt Re altime (n=1), ELITe ch Gro up (n=3), ELITe ch Gro up - Elite ch Elite Re al time kit(n=3), Anato lia Ge ne wo rks (n=1), Anato lia Ge ne wo rks - Anato lia Ge ne wo rks Bo sp ho re (n=1), Ro che (n=2), Ro che - Ro che Co b asTaq man (n=2), Ge ne Pro o f (n=2), Ge ne Pro o f - Ge ne Pro o f Re al Time PCR kit (n=2)

Groups Rolle d Up: b io Me rie ux - b io Me rie ux R-g e ne Quant Kit (n=7), Q IAGEN - Q iag e n Artus Re al Time (n=7)

10

Num


log Copies/ml

35

23

7

7

12

12

2 2.2 2.4 2.6 2.8 3 3.21.8

◉ Copie s/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


Range

(Log ) (n)




Groups Rolle d Up: b io Me rie ux - b io Me rie ux R-g e ne Quant Kit (n=7), Q IAGEN - Q iag e n Artus Re al Time (n=8 ), In-Ho use - Re al-timeIn-Ho use PCR (n=8 )

10

Num


log Copies/ml

32

24

7

8

8

1.5 2 2.5 3 3.5 4 4.5 5

◉ Copies/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


Range

(Log ) (n)




Groups Rolle d Up: b io Me rie ux - b io Me rie ux R-g e ne Quant Kit (n=7), Q IAGEN - Q iag e n Artus Re al Time (n=7), In-Ho use - Re al-timeIn-Ho use PCR (n=9 )

10

Num


log Copies/ml

31

22

7

7

9

1.8 2 2.2 2.4 2.6 2.8 3 3.2

◉ Copies/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


Range

(Log ) (n)



CORE 3.870 42 3.279 -5.535



10

Num


log Copies/ml

42

29

8

9

13

13

3 3.5 4 4.5 5 5.5 6

◉ Copie s/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


Range

(Log ) (n)



CORE 3.431 41 1.230 -4.271



10

Num


log Copies/ml

41

28

8

9

13

13

1 1.5 2 2.5 3 3.5 4 4.5

◉ Copie s/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


Range

(Log ) (n)



CORE 3.876 42 2.551 -5.775



10

Num


log Copies/ml

42

29

8

9

13

13

2 2.5 3 3.5 4 4.5 5 5.5 6

◉ Copie s/ml

► Commercial

■ bioMerieux

■ QIAGEN

► In-House


IndividualReport



Re f Code :CMVDNA17

Challe nge :S





CMVDNA17S-01 - Quant it at ive Result s Breakdo wn (IU/ml)




SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



Groups be low n=5: Ab b o tt (n=2), Ab b o tt - Ab b o tt Re altime (n=2), b io Me rie ux (n=1), b io Me rie ux - b io Me rie ux R-g e ne Quant Kit (n=1),Anato lia Ge ne wo rks (n=2), Anato lia Ge ne wo rks - Anato lia Ge ne wo rks Bo sp ho re (n=2), ELITe ch Gro up (n=1), ELITe ch Gro up - Elite chElite Re al time kit (n=1), Ro che (n=1), Ro che - Ro che Co b as (n=1), Ve la Diag no stics (n=1), Ve la Diag no stics - Ve la Dx Se nto sa(n=1), Sie me ns (n=1), Sie me ns - Sie me ns Ve rsant (n=1), Q IAGEN (n=1), Q IAGEN - Q iag e n Artus Re al Time (n=1), fast-trackDIAGNOSTICS (n=3), fast-track DIAGNOSTICS - FTD re al time PCR (n=3), RTA Lab o rato rie s (n=1), RTA Lab o rato rie s - RTALab o rato rie s Re al time (n=1)

Groups Rolle d Up: In-Ho use - Re al-time In-Ho use PCR (n=5), Alto na Diag no stics - Alto na Diag no stics Re alStar (n=7)

10

Num


log IU/ml

26

5

21

7

2 31.5 1.75 2.25 2.5 2.75 3.25 3.5

◉ IU/ml

► In-House

► Commercial

■ Altona Diagnostics

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



CORE 3.762 30 1.949 -4.457


Groups Rolle d Up: In-Ho use - Re al-time In-Ho use PCR (n=6 ), Alto na Diag no stics - Alto na Diag no stics Re alStar (n=8 )

10

Num


log IU/ml

30

6

24

8

2 2.5 3 3.5 4 4.51.5 5

◉ IU/ml

► In-House

► Commercial


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



CORE 3.920 30 2.823 -4.539







SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



10

Num


log IU/ml

30

6

24

8

3 42.5 2.75 3.25 3.5 3.75 4.25 4.5 4.75

◉ IU/ml

► In-House

► Commercial


10

Num

ber of Values in Groupslog IU/ml

25

21

7

2 32.25 2.5 2.75 3.25 3.5 3.75

◉ IU/ml

► Commercial


IndividualReport



Re f Code :CMVDNA17

Challe nge :S





Groups be low n=5: Ab b o tt (n=2), Ab b o tt - Ab b o tt Re altime (n=2), Anato lia Ge ne wo rks (n=2), Anato lia Ge ne wo rks - Anato liaGe ne wo rks Bo sp ho re (n=2), ELITe ch Gro up (n=1), ELITe ch Gro up - Elite ch Elite Re al time kit (n=1), Ro che (n=1), Ro che - Ro cheCo b as (n=1), Ve la Diag no stics (n=1), Ve la Diag no stics - Ve la Dx Se nto sa (n=1), Sie me ns (n=1), Sie me ns - Sie me ns Ve rsant (n=1),Q IAGEN (n=2), Q IAGEN - Q iag e n Artus Re al Time (n=2), fast-track DIAGNOSTICS (n=3), fast-track DIAGNOSTICS - FTD re al time PCR(n=3), RTA Lab o rato rie s (n=1), RTA Lab o rato rie s - RTA Lab o rato rie s Re al time (n=1), In-Ho use (n=4), In-Ho use - Re al-time In-Ho usePCR (n=4)

Groups Rolle d Up: Alto na Diag no stics - Alto na Diag no stics Re alStar (n=7)





SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



Groups be low n=5: Ab b o tt (n=2), Ab b o tt - Ab b o tt Re altime (n=2), Anato lia Ge ne wo rks (n=2), Anato lia Ge ne wo rks - Anato liaGe ne wo rks Bo sp ho re (n=2), ELITe ch Gro up (n=1), ELITe ch Gro up - Elite ch Elite Re al time kit (n=1), Ro che (n=1), Ro che - Ro cheCo b as (n=1), Sie me ns (n=1), Sie me ns - Sie me ns Ve rsant (n=1), Q IAGEN (n=2), Q IAGEN - Q iag e n Artus Re al Time (n=2), fast-trackDIAGNOSTICS (n=3), fast-track DIAGNOSTICS - FTD re al time PCR (n=3), RTA Lab o rato rie s (n=1), RTA Lab o rato rie s - RTALab o rato rie s Re al time (n=1), In-Ho use (n=4), In-Ho use - Re al-time In-Ho use PCR (n=4)

Groups Rolle d Up: Alto na Diag no stics - Alto na Diag no stics Re alStar (n=6 )

10

Num

ber of Values in Groupslog IU/ml

23

19

6

2 31.75 2.25 2.5 2.75 3.25 3.5

◉ IU/ml

► Commercial


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



Groups be low n=5: Ab b o tt (n=2), Ab b o tt - Ab b o tt Re altime (n=2), b io Me rie ux (n=1), b io Me rie ux - b io Me rie ux R-g e ne Quant Kit (n=1),Anato lia Ge ne wo rks (n=2), Anato lia Ge ne wo rks - Anato lia Ge ne wo rks Bo sp ho re (n=2), ELITe ch Gro up (n=1), ELITe ch Gro up - Elite chElite Re al time kit (n=1), Ro che (n=1), Ro che - Ro che Co b as (n=1), Sie me ns (n=1), Sie me ns - Sie me ns Ve rsant (n=1), Q IAGEN (n=2),Q IAGEN - Q iag e n Artus Re al Time (n=2), fast-track DIAGNOSTICS (n=3), fast-track DIAGNOSTICS - FTD re al time PCR (n=3), RTALab o rato rie s (n=1), RTA Lab o rato rie s - RTA Lab o rato rie s Re al time (n=1)


10

Num


log IU/ml

28

6

22

8

2 31.75 2.25 2.5 2.75 3.25 3.5 3.75

◉ IU/ml

► In-House

► Commercial


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



CORE 3.902 30 2.961 -4.436



10

Num


log IU/ml

30

6

24

8

3 42.75 3.25 3.5 3.75 4.25 4.5 4.75

◉ IU/ml

► In-House

► Commercial


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



CORE 3.746 30 2.895 -4.461



10

Num


log IU/ml

30

6

24

8

3 42.75 3.25 3.5 3.75 4.25 4.5 4.75

◉ IU/ml

► In-House

► Commercial


IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus

Conse nsus( IU/ml)

Range

(Log ) (n)



CORE 3.900 30 3.214 -4.462



Additional Information: Individual Panel Member Analysis (Qualitative)Qualitative analysis fo r each panel member is provided in relation to your EQA assessment group. EQA assessmentgroups are established using the molecular workflow information reported by all participants within this EQA challenge /distribution. The principal level o f assessment is at the individual method level which is defined based on your reported“amplification/detection method” and o ther laboratories using the same or similar amplification/detection methods.

To allow meaningful assessment at the individual method level the EQA assessment group must consist o f 5 or moredatasets. If there are not sufficient datasets at the individual method level then your results will be included within a higherEQA assessment group based on whether it is a commercial o r in house techno logy/method. The highest levelassessment grouping is “All” participant reported qualitative results.

A breakdown of qualitative results reported by participants on each o f the panel members within this EQA challenge /distribution is provided below. You can compare your results to those within your EQA assessment group and thoseobtained within o ther EQA assessment groups or to the overall consensus for each sample within this EQA challenge /distribution.

10

Num


log IU/ml

30

6

24

8

3.5 4 4.53 3.25 3.75 4.25 4.75

◉ IU/ml

► In-House

► Commercial


IndividualReport



Re f Code :CMVDNA17

Challe nge :S





CMVDNA17S-01 - Qualit at ive Result s Breakdo wn




SampleStatus

Pe rce ntageCorre ct All

(%) (n)

CMVDNA17S-01 CMV (AD169) Plasma D2, DS1_2 Detected EDUCATIONAL 92.3 78

Groups be low n=5: In-Ho use - Co nve ntio nal In-Ho use PCR (n=2), b io Me rie ux - Bio Fire FilmArray (n=1), Vitassay (n=1), Vitassay -Vitassay Re al-Time PCR (n=1), Ab b o tt (n=1), Ab b o tt - Ab b o tt Re altime (n=1), Anato lia Ge ne wo rks (n=3), Anato lia Ge ne wo rks -Anato lia Ge ne wo rks Bo sp ho re (n=3), Ce rte st (n=1), Ce rte st - Ce rte st Re al Time PCR (n=1), Diag e no d e (n=2), Diag e no d e -Diag e no d e Re al Time kit (n=2), Sie me ns (n=1), Sie me ns - Sie me ns Ve rsant (n=1), Patho Find e r (n=1), Patho Find e r - Patho Find e r RTPCR (n=1), Ge ne Pro o f (n=2), Ge ne Pro o f - Ge ne Pro o f Re al Time PCR kit (n=2), Maste r Diag no stica (n=1), Maste r Diag no stica -Maste r Diag no stica Flo w Chip (n=1)

Groups Rolle d Up: ELITe ch Gro up - Elite ch Elite Re al time kit (n=5), fast-track DIAGNOSTICS - FTD re al time PCR (n=6 ), Alto naDiag no stics - Alto na Diag no stics Re alStar (n=8 ), Q IAGEN - Q iag e n Artus Re al Time (n=8 )

Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group

■ fast- track DIAGNOSTICS

■ bioMerieux

● bioMerieux R-gene Quant Kit


■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)



CORE 100.0 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)

CMVDNA17S-03 CMV (AD169) Plasma D1, DS1_1 FrequentlyDetected

CORE 100.0 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)


Plasma D4, DS2_2 Detected EDUCATIONAL 93.6 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)

CMVDNA17S-05 CMV (AD169) Plasma D2, DS1_2 Detected EDUCATIONAL 92.3 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)


Plasma D4, DS2_2 Detected EDUCATIONAL 94.9 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)


CORE 100.0 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)



CORE 97.4 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)

CMVDNA17S-09 CMVNegative

Plasma Negative CORE 98.7 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S









SampleStatus


(%) (n)


CORE 100.0 78



Num


Inco rrect Co rrect

78

26

24

52

5

6

12

11

8

8

0% 20% 40% 60% 80% 100%

0% 20% 40% 60% 80% 100%

◉ All

► In-House


► Commercial

■ ELITech Group


■ bioMerieux



■ QIAGEN

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





QCMD © 2016 . The QCMD EQA p ro g ramme samp le s, asso ciate d re p o rts and d ata g e ne rate d d uring this p ro g ramme are inte nd e dfo r Exte rnal Quality Asse ssme nt (EQA) and Pro fic ie ncy Te sting (PT) p urp o se s o nly. QCMD o p e rate s acco rd ing to a stric t Co d e o fPractice which is in l ine with ISO/IEC 170 43 and asso ciate d stand ard s. Data re p o rte d in QCMD p ro g ramme s is re p re se ntative o f alab o rato ry's stand ard d iag no stic te sting p ro to co ls irre sp e ctive o f the te chno lo g y the y use . The d ata p ro vid e d in the re p o rts areb ase d o n te chnical info rmatio n p ro vid e d b y the ind ivid ual lab o rato rie s as p art o f the asse ssme nt p ro ce ss, as such it d o e s no tco nstitute a fo rmal te chno lo g y me tho d co mp ariso n. All te xt and imag e s p ro d uce d b y QCMD are the p ro p e rty o f QCMD unle sso the rwise state d .

The re p ro d uctio n and use o f the se mate rials is no t p e rmitte d witho ut the e xp re ss writte n co nse nt o f QCMD. The use o f theinfo rmatio n p ro vid e d in QCMD re p o rts fo r co mme rcial p urp o se s is stric tly p ro hib ite d .

IndividualReport



Re f Code :CMVDNA17

Challe nge :S





Individual QCMD 2017 Human Cytomegalovirus Report DNA EQA ...

Documents

Transcript of Individual QCMD 2017 Human Cytomegalovirus Report DNA EQA ...